New data supports earlier use of evolocumab in high-risk diabetes Adding the PCSK9 inhibitor evolocumab to a high-intensity, cholesterol-lowering regimen reduced the risk of a first major cardiovascular event among adults with atherosclerotic cardiovascular disease (ASCVD) or diabetes , according to a preliminary late-breaking science presentation today at the American Heart Association's Scientific Sessions 2025.
https://www.news-medical.net/n....ews/20251111/New-dat